The preclinical in-vivo imaging market in Europe is growing faster from the past few years and is to hit the highest CAGR in the review period. Preclinical in-vivo imaging plays a crucial role in the research centers while developing new techniques. It has many applications in manufacturing a new drug. It ensures the safety and effectiveness of the new drug developed before clinical use. It helps to have a clear visualization of living animals while performing preclinical research. Modern technologies are taking part in manufacturing highly specified features in the preclinical in-vivo imaging market. Different techniques are used for anatomical imaging and molecular visualizations in research centers and theses techniques will determine changes in animals responding to physiological and environmental changes at the organ, tissue or molecular levels.
Increasing incidences of various health disorders especially cancer and cardiovascular problems is boosting up the demand of the market in Europe. Also, the growing prevalence of the effective treatment procedures at any cost along with increasing disposable income is lavishing the growth rate of the preclinical in-vivo imaging market. Escalating expenditure on healthcare is also one of the factors propelling the demand of the market to the extent. The rise in the awareness of anatomical imaging techniques is expanding the growth rate of the market.
However, the cost of installation and maintenance of the equipment is a bit expensive and cannot be affordable by small scale organizations. This attribute is slowly hindering the demand of the market. Lack of standardization is also inhibiting the growth rate of the market. The major challenging factor for the market lies in the less availability of skilled technicians and also growing complex issues in real-time.
Rising support from government and non-government bodies through investments in developing new drugs with high quality is creating growth opportunities for the market. Besides, the emergence of advanced technology and the launch of innovative products are promoting the growth rate of the preclinical in-vivo imaging market in Europe.
This research report segmented and sub-segmented into the following categories:
By Modality: optical Imaging, Nuclear Imaging, Micro-MRI, Micro-CT, Micro-ultrasound, Photoacoustic and Magnetic Particle Imaging Systems
Based on the modality, the optical imaging segment is leading with the highest shares of the market. Increasing demand for the detection of diseases at an early stage to have appropriate treatment procedures is leveraging the demand of the market. The rise in the funds on the development of new products with the latest technology is elevating the growth rate of the market.
By Reagent: Optical Imaging Reagents, Nuclear Imaging Reagents, MRI Contrast Agents, Ultrasound Contrast Agents and CT Contrast Agents
Optical imaging reagents are witnessed in holding the largest shares of the market whereas nuclear imaging reagents are growing at a faster rate. On-going research on developing new techniques in imaging to promote better outcomes is surging the growth rate of the market.
By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe
Geographically, Europe is leading with the highest shares of the market. Germany and UK are among major countries contributing the largest shares to the market with the increased revenue and also rising elderly population. France, Italy, and Spain among other countries in Europe are to have a significant growth rate in the coming years.
Top companies in this market
MR Solutions (UK), Mediso Miltenyi Biotec GmbH (Germany) and others are key players in the Europe preclinical in-vivo imaging market.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Modality
5.1.1 Optical imaging
5.1.1.1 Bioluminescence/fluorescence imaging systems
5.1.1.2 Standalone fluorescence imaging systems
5.1.1.3 Optical + X-ray/optical + CT imaging systems
5.1.2 Nuclear imaging
5.1.2.1 Micro-PET systems (standalone PET, PET/CT, and PET/MRI)
5.1.2.2 Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI)
5.1.2.3 Tri-modality (PET/SPECT/CT) imaging systems
5.1.3 Micro-MRI
5.1.4 Micro-CT
5.1.5 Micro-ultrasound
5.1.6 Photoacoustic
5.1.7 Magnetic particle imaging systems
5.2 By Reagent
5.2.1 Optical imaging reagents
5.2.1.1 Bioluminescent reagents
5.2.1.2 Fluorescent imaging reagents
5.2.2 Nuclear imaging reagents
5.2.2.1 Preclinical PET tracers
5.2.2.2 Preclinical SPECT probes
5.2.3 MRI contrast agents
5.2.4 Ultrasound contrast agents
5.2.5 CT contrast agents
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Aspect Imaging
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Biospace Lab S.A.
8.3 Bruker Corporation
8.4 LI-COR Biosciences
8.5 Mediso Ltd.
8.6 MILabs B.V.
8.7 MR Solutions Ltd
8.8 PerkinElmer
8.9 TriFoil Imaging
8.10 FUJIFILM VisualSonics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
